Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12098-024-05329-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cervical Spine Range of Motion and Sleep Disturbances in Patients With Atopic Dermatitis: A Cross-Sectional Study.
Cureus
December 2024
Department of Clinical Anatomy, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, JPN.
Background: Sleep disturbances are common and distressing among patients with atopic dermatitis (AD), often resulting in a cycle of worsening skin conditions. Among various factors affecting sleep in AD, cervical spine movement has been suggested to influence sleep quality; however, these studies mostly relied on subjective measures. Owing to the lack of objective and quantitative analyses of cervical spine movement, its association with sleep disturbances remains poorly understood.
View Article and Find Full Text PDFIdentification of Early and Late Responders to Anti-IL-13 Antibody Tralokinumab in Atopic Dermatitis: A Real-World Japanese Study.
Dermatitis
December 2024
From the Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
Tralokinumab, an anti-IL-13 antibody, is an effective treatment for patients with atopic dermatitis (AD). However, predictive factors for responders to tralokinumab remain unclear in real-world practice. This study aimed to identify predictive factors for early and late responders to tralokinumab treatment.
View Article and Find Full Text PDFImmunotherapy using pullulan-conjugated Der f 2 allergen in canine atopic dermatitis: An anti-inflammatory agent-sparing approach.
Vet Dermatol
December 2024
Zenoaq, Koriyama, Fukushima, Japan.
Background: Allergen immunotherapy is used as aetiological treatment for canine atopic dermatitis (cAD).
Objective: To assess the anti-inflammatory agent-sparing effect over 1 year of immunotherapy using pullulan-conjugated recombinant Der f 2 (rDf2-P).
Animals: Twenty-one privately owned dogs with cAD.
Reliea® combination of Codonopsis lanceolata and Chaenomeles sinensis extract alleviates airway inflammation on particulate matter 10 plus diesel exhaust particles (PMD) ‑induced respiratory disease mouse model.
Ecotoxicol Environ Saf
December 2024
Institute of Traditional Medicine and Bioscience, Daejeon University, Daejeon 34520, Republic of Korea. Electronic address:
Particulate matter (PM, diameter < 10 μm) and Diesel exhaust particles (DEP) exposure can cause severe respiratory disorders. This investigation explored the protective effects of Reliea® (RelA), combination of Codonopsis lanceolata and Chaenomeles sinensis extract, against airway inflammation related to PMD exposure. RelA treatment suppressed reactive oxygen species, nitric oxide release, cytokine expression (IL-6, IL-1β, iNOS, CXCL-2, MCP-1, and TNF-α), and the related inflammatory mechanisms in PM-induced alveolar macrophage cells.
View Article and Find Full Text PDFPredictive Factors for Primary and Secondary Nonresponders to Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Study.
Dermatitis
December 2024
From the Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
Article Synopsis
- * A study conducted from August 2021 to March 2024 analyzed 204 Japanese AD patients, comparing clinical and lab data between those who responded and those who did not respond to the treatment.
- * Findings indicated primary nonresponders had higher levels of eczema severity and various inflammatory markers, while secondary nonresponders were more likely to have used previous systemic treatments like dupilumab or corticosteroids.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!